Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Akeso shares plummet as Chinese firm’s cancer drug ivonescimab faces FDA setback

Shares in Hong Kong-listed Akeso plunged as much as 31.8 per cent on Monday morning after the US Food and Drug Administration (FDA) rejected its cancer drug application, raising investor worries over the company’s near-term commercial outlook. Ivonescimab, one of the most closely watched innovative drugs emerging from China, did not establish “substantial evidence of effectiveness”, said US firm…

Akeso shares plummet as Chinese firm’s cancer drug ivonescimab faces FDA setback

We haven't written up this one. SCMP Business has the full story — the link below goes straight to it.

This story

This is one outlet's version. Read the fullest account.

Every outlet that reported this, and when →

Read the original at scmp.com →

More in Health & Medicine

Ethiopia: The Bone-Setters' Ward - How Ancient Healers Are Filling Ethiopia's Modern Healthcare Vacuum

[African Arguments] In a residential neighbourhood of Bahir Dar, in northwestern Ethiopia, patients visit the home of W/ro Birqe Yibre for help with injuries.

  • W/ro Birqe Yibre practices traditional bone-setting in Bahir Dar, Ethiopia.
  • 46.05% of injured individuals in Mecha district use traditional bone-setting services.
  • Dr. Biruk Ferede warns against complications from manipulating fractures and tight splinting.

More from Monday 16 November →